Search

Soluble intercellular adhesion molecule-1 (sICAM-1) is ranked as one of the endothelial dysfunction markers and factors predicting diseases of the cardiovascular system. The main objective of this study was to assess the serum concentration of sICAM-1 in women with polycystic ovary syndrome (PCOS) and to verify correlations between serum sICAM-1 levels and selected anthropometric, metabolic and hormonal indices. The study assessed 57 women with PCOS (mean age 28.2 +/- 6.4 years). That group was further divided into two subgroups: the first with body mass index (BMI)or =25 kg/m2 (21 women of mean age 27.4 +/- 7.0 years) and the second with BMI25 kg/m2 (36 women of mean age 28.6 +/- 6.0 years). In the control group there were 22 healthy women (mean age of 31.6 +/- 8.5 years). That group again was divided accordingly to BMI into two subgroups: the first with BMI25 kg/m2 (ten women, mean age 30.2 +/- 8.4 years) and the second with BMI25 kg/m2 (12 women, mean age 31.7 +/- 8.7 years). The results demonstrated statistically significantly higher mean concentrations of sICAM-1 in women with PCOS as compared to healthy individuals from the whole control group and also from the control subgroup of women with BMI25 kg/m2. There was no statistically significant difference in sICAM-1 concentration between the PCOS group and the control subgroup with BMIor =25 kg/m2 In conclusion, higher concentrations of sICAM-1 in women with PCOS may confirm the presence of a higher risk for cardiovascular diseases in this group. Further studies are therefore necessary to identify both the factors that are responsible for the increase in sICAM-1 concentration and the clinical usefulness of routine sICAM-1 measurement in females with PCOS.

It is well known that there is a higher prevalence of cardiovascular risk factors and metabolic syndrome (MS) in postmenopausal women. Recently it has become evident that adiponectin and leptin secreted by adipose tissue may be involved in the pathophysiology of MS.was to assess the effects of the menopause on the relationships between adiponectin and leptin and different cardiovascular and metabolic risk factors.A total of 56 postmenopausal women and 75 premenopausal subjects were enrolled in this study. We measured blood pressure, BMI, waist circumference and WHR, triglycerides (TG), high density lipoprotein cholesterol (cHDL) levels and fasting glucose and applied the oral glucose tolerance test (OGTT). Women were categorised as having 0, 1, 2, 3 or more risk factors. The presence of at least 3 abnormalities was defined as MS. Serum was assayed for adiponectin and leptin by the radioimmunoassay (RIA) method.A decline in adiponectin was related to an increased number of MS variables in postmenopausal and premenopausal women. Postmenopausal women with MS had significantly lower adiponectin concentrations than premenopausal women with MS. Serum adiponectin concentrations were inversely correlated to leptin in postmenopausal women. In premenopausal women no clear relationships were found between serum leptin and the number of metabolic disturbances. In contrast to young women, postmenopausal women showed an increase in leptin secretion with a growing number of MS elements. Compared to premenopausal women with MS, postmenopausal women with MS had higher levels of leptin. We found associations between leptin and different risk factors, mainly in the postmenopausal group. When the presence of MS was used as a dependent variable (yes/no) and adiponectin, leptin and menopause status as independent factors, adiponectin and leptin remained significant variables related to MS.The significant role of adiponectin in the pathophysiology of MS in premenopausal and postmenopausal women is confirmed in this study. Leptin is correlated with several MS components but this adipocytokine appears to play a role only in postmenopausal women.

The aim of the study was to check if in postmenopausal women such a disease as asthma and use of hormone replacement therapy (HRT) influence daily melatonin (MEL) secretion.Studies were performed in 55 asthmatics (treated and not treated with glucocorticosteroids) and 20 healthy postmenopausal women (aged 48-60) before HRT and after 6 months of transdermal 17beta-estradiol and medroxyprogesterone acetate treatment (cyclical method). During the circadian study blood samples for the measurement of MEL were collected every 3 hours during the day. MEL concentrations were assessed with the use of RIA methods. Statistical analysis of the circadian rhythm was performed with the use of cosinor test according to Halberg et al.Existence of daily rhythm of MEL secretion was shown in all studied groups, before as well as after HRT. A significant decrease of mesor and amplitude's rhythm was observed in the group of women with asthma treated with glucocorticosteroids (GC) before and after HRT use in relation to women not treated with GC and the control group. Secretion of MEL in these patients was lower at nocturnal hours. A significant decrease of mean daily MEL secretion in relation to values before HRT use was shown in all groups.Asthmatic postmenopausal women treated with GC show lowered circadian secretion of melatonin as a consequence of lowering its secretion at nocturnal hours. Hormonal replacement therapy causes a decrease of daily melatonin secretion in healthy as well as asthmatic women, not disturbing circadian rhythm of this hormone's secretion.